DALK with hydrops is safe and effective

Article

Deep anterior lamellar keratoplasty (DALK) is a safe and effective procedure in keratoconic eyes with previous hydrops.

Deep anterior lamellar keratoplasty (DALK) is a safe and effective procedure in keratoconic eyes with previous hydrops.

The retrospective, non-comparative study, led by Sheraz M Daya, Centre for Sight, East Grinstead, UK, involved 10 eyes of 10 patients. Each patient has previously receieved hydrops and underwent DALK.

DALK was completed using the Melles's technique of optical recognition with pre-Descemet's membrane dissection. The outcome measures included preoperative and postoperative uncorrected distance visual acuity and best spectacle corrected distance visual acuity (BSCVA), postoperative spherical equivalent (SEQ), keratometry and adverse events.

Preoperative BSCVA was 6/24 or worse in all eyes and at the last follow-up it was 6/12 or better in all eyes. Six eyes experienced intraoperative microperforation but penetrating keratoplasty conversion was not required.

The mean SEQ was −2.4±4.2 D, keratometric astigmatism was 3.8±1.6 D and refractive astigmatism was 3.4±2.2 D, whereas the mean postoperative keratometry was 43.7±2.6 and central pachymetry 572.6±65.0 µm.

The study can be found in the British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.